Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis

2021 ◽  
Author(s):  
Patricia Dias-Carvalho ◽  
Flavia Martins ◽  
Susana Mendonca ◽  
Andreia Ribeiro ◽  
Ana Luisa Machado ◽  
...  

Genetic alterations influence the malignant potential of cancer cells, and so does the tumor microenvironment. Herein, we combined the study of KRAS oncogenic effects in colorectal cancer cells with the influence of fibroblasts derived factors. Results revealed that mutant KRAS regulates cell fate through both autonomous and non autonomous signaling mechanisms. Specifically, processes such as proliferation and cell-cell aggregation were autonomously controlled by mutant KRAS independently of the stimulation with fibroblasts conditioned media. However, cancer cell invasion revealed to be a KRAS dependent non-autonomous effect, resulting from the cooperation between fibroblasts-derived HGF and mutant KRAS regulation of C-MET expression. C-MET downregulation upon KRAS silencing rendered cells less responsive to HGF and thus less invasive. Yet, in one cell line, KRAS inhibition triggered invasion upon stimulation with fibroblasts conditioned media. Inhibition of PIK3CA oncogene did not promoted invasion, thus showing a KRAS specific effect. Moreover, the invasive capacity also depended on the HGF-C-MET axis. Overall, our study awards oncogenic KRAS an important role in modulating the response to fibroblast-secreted factors either by promoting or impairing invasion, and depicts the HGF-C-MET axis as a putative therapeutic target to impair the invasive properties of mutant KRAS cancer cells.

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e74982 ◽  
Author(s):  
Sofia Edin ◽  
Maria L. Wikberg ◽  
Jörgen Rutegård ◽  
Per-Arne Oldenborg ◽  
Richard Palmqvist

2017 ◽  
Vol 4 (S) ◽  
pp. 68
Author(s):  
Hong-Quan Duong

Colorectal carcinomas are characterized by multiple genetic alterations, including constitutive Wnt activity and gain-of-function mutations in K-RAS and B-RAF. BRAF encodes a Ser/Thr kinase acting in the Ras/MEK/ERK pathway and the V600E mutation found in 11% of colorectal cancers renders this kinase constitutively active. B-RAF mutated colorectal carcinomas represents a very aggressive entity with a poor prognosis. Understanding the molecular mechanisms activated downstream of mutated B-RAF is urgently needed to design new therapeutic avenues to treat B-ARF mutated colorectal carcinomas and to circumvent resistance to therapies targeting the Ras/Raf/MEK1/ERK1/2 pathway. In a search for candidates that critically contribute to both intrinsic and acquired resistance to MEK1 inhibition in B-RAF mutated colorectal cancer cells, we identified one scaffold protein whose expression is driven by both NF-kB and AP-1 families of transcription factors. This scaffold protein promotes the expression of HER2 and HER3 in colorectal cancer cells subjected to MEK1 or B-RAF inhibition (Selumetinib and Vemurafenib, respectively) and, as such, is critically involved in the intrinsic resistance to these targeted therapies. The same scaffold protein is also strongly induced in B-RAF but not K-RAS mutated colorectal cancer cells showing acquired resistance to MEK1 inhibition. Interfering with the expression of this scaffold protein circumvents both intrinsic and acquired resistance to Selumetinib in B-RAF mutated colorectal cancer cells. Our study defines a new molecular actor critically involved in oncogenic signaling pathways triggered by mutated B-RAF. Our study also defineS new combinatory therapies to better treat B-RAF-mutated colorectal carcinomas.


2019 ◽  
Vol 234 (10) ◽  
pp. 18249-18261 ◽  
Author(s):  
Jeong‐Hyeon Ko ◽  
Jae‐Young Um ◽  
Seok‐Geun Lee ◽  
Woong Mo Yang ◽  
Gautam Sethi ◽  
...  

2020 ◽  
Vol 21 (2) ◽  
Author(s):  
Peng Ge ◽  
Ching Yi Ong ◽  
Abdalla Eshtiyag Abdalkareem ◽  
Boon Yin Khoo ◽  
Bo Yuan

Sign in / Sign up

Export Citation Format

Share Document